JUPITER, Fla., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (OTCQX:DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Arindam Bose, Ph.D., to its Board of Directors, effective August 15, 2016.
Dr. Bose recently retired from Pfizer Research & Development after serving for 34 years, most recently in senior leadership roles in process development and manufacturing of biologics. Specifically, for the last six years, Dr. Bose served as Vice President of Bio Therapeutics Pharmaceutical Sciences External Affairs and Biosimilars Strategy. In that role, Dr. Bose led the technical team which was responsible for researching, developing and executing Pfizer’s strategy for entry into the emerging field of biosimilars. That effort resulted in the successful submission of 5 Investigational New Drug Applications (INDs) to the FDA: all 5 of which have already progressed to Phase 3 testing. Dr. Bose was also a member of Pfizer’s Bioprocess Leadership Team (BPLT) – Pfizer’s most senior oversight team for biotechnology product technical development and manufacturing.
“We are very excited that Dr. Bose has joined Dyadic’s board of directors,” said Mark Emalfarb, Dyadic’s CEO. “His extensive background in biologics products, process development and commercial experiences make him an ideal scientific and business advisor to provide guidance and insight to Dyadic’s biologics business strategy and research initiatives.” Mr. Emalfarb continued, “Dr. Bose has an extensive global network of key business and research relationships that we expect will help us accelerate the introduction and adoption of our C1 technology in the biotech and pharmaceutical industry for use in the development and manufacture of biologic vaccines and drugs.”
Dr. Bose commented, "I am truly excited to join the Dyadic Board of Directors. I view the C1 technology platform as a leap in technology that has the potential to change the way in which both animal health and human biotech and pharmaceutical companies bring their biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with newer beneficial properties.”
Prior positions held by Dr. Bose at Pfizer included: Executive Director, Human Biologics Strategy & Sourcing (2003-2009), Director, Human Biologicals (2000-2003), Senior Technical Advisor, Human Biologicals (1997-2000), and Manager, Bioprocess Development (1991-1997).
Dr. Bose began his career as a research scientist at the Battelle Memorial Institute where he worked on biochemical process technology. He received a Ph.D. in chemical engineering from Purdue University and a M.S. in chemical engineering from the University of Michigan, Ann Arbor. Dr. Bose was elected a Fellow of the American Chemical Society, American Institute of Chemical Engineers and American Institute for Medical and Biological Engineering in recognition of his outstanding professional accomplishments.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant protein production system based on the fungus Myceliopthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, production and performance of biologic drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in developing and manufacturing biopharmaceuticals which these technologies help produce. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly saving lives. Please visit Dyadic’s website at www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.